Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578625 | PMC |
| http://dx.doi.org/10.2215/CJN.0000000000000241 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world experience of tixagevimab/cilgavimab prophylaxis in Japanese patients with immunodeficiency.
J Infect Chemother
December 2024
Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, 113-8519, Tokyo, Japan. Electronic address:
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe illness and mortality in patients with immunodeficiency. Although vaccination has been recommended, the induction of protective antibodies by immunization, and thus the disease-preventive effect, has proven insufficient in immunodeficient patients, especially in those with predominantly antibody deficiency. A monoclonal antibody combination of tixagevimab and cilgavimab (TIX/CIL) was developed as a pre-exposure prophylaxis (PrEP).
View Article and Find Full Text PDFPre-exposure prophylaxis for COVID-19 with Tixagevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center Experience.
New Microbiol
November 2024
Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples "Federico II", Naples, Italy.
Article Synopsis
- Pre-exposure prophylaxis with Tixagevimab/Cilgavimab has effectively reduced COVID-19 risks in immunocompromised patients, but its efficacy is limited against the Kraken variant (XBB.1.5).
- A study involving kidney transplant patients on this treatment showed only one asymptomatic infection during a six-month follow-up, with no hospitalizations or COVID-related deaths.
- The results suggest Tixagevimab/Cilgavimab may still be a beneficial preventive option for immunocompromised individuals, underlining the need for further clinical research on this topic.
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
J Infect
November 2024
Infectious Diseases Division, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Background: The clinical effectiveness of early therapies for mild-to-moderate COVID-19, comparing antivirals and monoclonal antibodies (mAbs) during the Omicron era, has not been conclusively assessed through a post-approval comparative trial. We present a pooled analysis of two randomized clinical trials conducted during Omicron waves.
Methods: The MANTICO2/MONET trial is a pooled analysis of two multicentric, independent, phase-4, three-arm, superiority, randomized, open-label trials.
Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study.
Viruses
August 2024
Infectious Diseases Unit, Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, 11527 Athens, Greece.
Background: COVID-19 continues to pose a threat to immunocompromised individuals, even with vaccination. The monoclonal antibodies (mAbs) tixagevimab/cilgavimab (TXG/CIL) provide targeted prophylaxis against SARS-CoV-2 with the benefit of a prolonged half-life. Although approved for COVID-19 prevention, there is limited data on their effectiveness among heavily immunocompromised populations.
View Article and Find Full Text PDFTixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients-A Tailored Approach Based on SARS-CoV-2 Vaccine Response.
Vaccines (Basel)
August 2024
TUM School of Medicine and Health, Department of Internal Medicine III, University Medical Center, Technical University of Munich, 81675 Munich, Germany.
Patients with hematologic malignancies still face a significant risk of severe coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-neutralizing monoclonal antibody combination tixagevimab/cilgavimab (TIX/CGB) could be administered to immunocompromised patients for pre-exposure prophylaxis (PrEP) before the emergence of TIX/CGB-resistant COVID-19 Omicron variants. TIX/CGB application could be carried out regardless of the host's immune response to previous active SARS-CoV-2 vaccinations or infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!